LENZ (lenzilumab) / Humanigen 
Welcome,         Profile    Billing    Logout  
 16 Diseases   3 Trials   3 Trials   683 News 


«1234567»
  • ||||||||||  lenzilumab (KB003) / Humanigen
    Look at Lenzilumab (Twitter) -  Feb 12, 2022   
  • ||||||||||  lenzilumab (KB003) / Humanigen
    Lenzilumab in Hospitalized Black/African-American COVID-19 Patients: Live-Air Phase 3 Study Results ([VIRTUAL]) -  Feb 8, 2022 - Abstract #SCCM2022SCCM_853;    
    In LIVE-AIR, with a B/AA representation comparable to the US population and usually under-represented in trials, lenzilumab improved the likelihood of SWOV across races and ethnicities of COVID-19 patients; however, B/AA with baseline CRP< 150 mg/L exhibited a markedly greater improvement. Biological, genetic, and social factors contributing to these differences requires further investigation.
  • ||||||||||  LENZ (lenzilumab) / Humanigen
    Enrollment closed, Trial completion date, Trial primary completion date:  ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19 (clinicaltrials.gov) -  Feb 4, 2022   
    P2,  N=473, Active, not recruiting, 
    Biological, genetic, and social factors contributing to these differences requires further investigation. Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> Oct 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
  • ||||||||||  lenzilumab (KB003) / Humanigen
    Optimized Inhibition of GM-CSF in Preclinical Models of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy (Salt Palace Convention Center Hall A) -  Jan 9, 2022 - Abstract #TCTASTCTCIBMTR2022TCT_ASTCT_CIBMTR_864;    
    Having demonstrated that GM-CSFRα is significantly upregulated on stimulated CART19, we aimed to determine the impact of GM-CSF neutralization (lenzilumab, 10 µg/mL) versus GM-CSFRα blockade (research-grade, 10 µg/mL) on CART19 function and CART cell-monocyte interactions...Flow cytometric analysis revealed that GM-CSF neutralization, but not GM-CSFRα blockade, mitigated monocyte suppression of CART19 antigen specific proliferation (Fig 1B). In summary, our findings indicate significant differences on CART cell functions and CART cell-monocyte interactions when a specific cytokine, GM-CSF, is neutralized compared to blocking its receptor.